- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Melinda Magyari Explains the Treatment Landscape for Pediatric-Onset MS
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).
Transcript
What does the treatment paradigm for pediatric MS look like today?
That's a good question, but we have the recommendation from the international multiple sclerosis group that disease-modifying treatment should be initiated in children with MS. Of course, the benefit/risk should be also taken into consideration, so the treatment paradigm in most of the countries is escalation therapy, starting with a mild, moderately effective drug in mild and moderate diseases activity. But I see in our registry and also in others that children with highly active disease are initiated with more effective therapies.
